Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.22.65 (Der p 1)
 346 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Der p 1 is a major allergen that reacts with IgE in more than 70% allergic sera, hence a good candidate for DNA vaccine development. Previous study demonstrated that intramuscular injection of plasmid DNA containing wild type Der p 1 gene induced specific Th1 skewed immune response. The aim of this study is to further optimize the DNA construct to achieve preventive and therapeutic efficacies. An optimized construct, containing mouse Igkappa light chain leader sequence followed by codon optimized mature Der p 1 gene, was generated and used to prevent or treat Der p1 induced allergic asthma in an experimental model. Results showed that this optimized construct was effective in the inhibition of Der p 1 specific IgE levels, attenuation of Th2 response and reduction of airway hyperresponsiveness in terms of prophylactic efficacy. It also showed therapeutic efficacy in IgE inhibition and up-regulation of IgG2a and IFN-gamma. The information obtained here could facilitate the design of DNA vaccines for allergy in general.
 ...
PMID:Efficacy evaluation of Der p 1 DNA vaccine for allergic asthma in an experimental mouse model. 1615 54

Although clinical and laboratory evidence support roles for both staphylococcal infection and environmental allergens in the pathogenesis of atopic dermatitis, human studies have largely considered these variables independently. We sought to test the hypothesis that staphylococcal superantigen influences the allergen-specific T cell response. We first mapped a Der p 1 epitope and used HLA DRB1*1501 class II tetramer-based cell sorted populations to show that specific CD4(+) T cells were able to recognize the peptide presented by HLA DR-matched keratinocytes. We observed that staphylococcal enterotoxin B (SEB) enhanced the IL-4 Der p 1-specific T cell response. This response was mediated by two synergistic mechanisms: first, SEB-induced IFN-gamma promoted class II and intercellular adhesion molecule-1 expression by presenting keratinocytes; and second, SEB-induced IL-4 directly amplified allergen-specific CD4(+) T cell production of many cytokines. We propose that handling of staphylococcal infection is a critical step in the amplification of the allergen-specific T cell response, linking two common disease associations and with implications for the prevention and treatment of atopic disease.
 ...
PMID:Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. 1737 19

The influence of different treatment schedules of sublingual immunotherapy (SLIT) in activating IL-10-producing T-cells, crucial in inducing allergen-specific tolerance, is not completely understood. The present work was designed to evaluate allergen driven interleukin release by mononuclear cells in the early phase of SLIT, after application of different induction schemes. Twenty mite-allergic patients were enrolled, 10 (group A) treated with a traditional 98 day induction scheme and 10 (group B) with a 16 day scheme with monomeric allergoid vaccine. At the end of the induction phase, the cumulative doses taken by group A and group B patients were equivalent to 50.5 and 50.3 microg of mite group 1 allergens, respectively. The release of Th1-, Th2- and Treg-related interleukins was assessed in culture supernatants of 5 microg/ml Der-p1-stimulated mononuclear cells, isolated before and after the induction phases. No relevant treatment-related side effects were observed. Interleukin release was similar in the two groups at the enrolment. Non-stimulated and Der p 1 stimulated release of studied cytokines was similar in the two groups at enrolment. Der p 1 stimulation significantly increased IL-10 release (p<0.0002) after treatment in group B patients, and this effect was higher (p=0.05) compared to group A patients. Furthermore, at the end of SLIT induction TNF-alpha, IL-4 and IFN-gamma production were reduced in group B patients (p<0.05, p=0.062 and p=0.060, respectively). The rapid induction scheme of sublingual immunotherapy induces an early immune suppression more effectively than the slower one. The rapid induction scheme should be the preferential way to start sublingual immunotherapy, particularly when monomeric allergoids are utilized.
 ...
PMID:Early cytokine modulation after the rapid induction phase of sublingual immunotherapy with mite monomeric allergoids. 1914 82


<< Previous 1 2 3